Switching and Escalating Therapy in Long-Lasting Multiple Sclerosis: Not Always Necessary. (22nd December 2012)

• Record Type: Journal Article
• Authors: Carvalho, Ana Teresa; Sá, Maria José
• Other Names: Dorovini-Zis K. Academic Editor.; Joosten E. A. Academic Editor.; Müller T. Academic Editor.; Ohyagi Y. Academic Editor.; Sunada Y. Academic Editor.; Weis S. Academic Editor.
• Is Part Of: ISRN neurology. Volume 2012(2012)
• Publication Date: 2012-12-22
• Subjects: Neurology -- Periodicals; Nervous System Diseases; Neurology; Neurology; Periodicals; 616.8
• DOI: 10.5402/2012/451457
• Languages: English
• ISSNs: 2090-5505

Abstract

Abstract : Although therapy switch is common among patients with multiple sclerosis (MS), sometimes the initial prescribed treatment is maintained for a long period with clinical stability, low disability, and nonsignificant side effects. We aim to describe demographic and clinical characteristics of patients treated in our MS clinic with the same disease-modifying drug (DMD) lasting for >12 years. From the cohort of 51 patients followed in our MS clinic with relapse-remitting MS who started an DMD between 1996 and 1999, we found a high percentage (51%) of patients who were efficiently treated with the first DMD. These patients were mainly females, with low annualized relapse rate and Multiple Sclerosis Severity Score (MSSS). Our results may be related to the open and multidisciplinary model of our MS clinic organization. Identifying characteristics associated with therapy persistence may be useful in developing strategies to improve therapy effectiveness.